Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Inhibrx Reports Second Quarter 2026 Financial Results PR Newswire - Thu Aug 13, 3:04PM CDT

SAN DIEGO , Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical...

INBX : 91.96 (+4.06%)
Inhibrx Reports Tomorrow With Analysts Bracing for Wider Loss Barchart - Tue Aug 11, 4:04PM CDT

Barchart Research What to Expect from INBX Earnings INBX Generated August 11, 2026 Current Price $92.38 EPS Estimate $$-2.50 Consensus Rating Moderate Buy Average Move 4.17% Inhibrx Reports Tomorrow With...

INBX : 91.96 (+4.06%)
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire - Thu Jul 16, 8:00AM CDT

SAN DIEGO , July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 91.96 (+4.06%)
Inhibrx Reports First Quarter 2026 Financial Results PR Newswire - Thu May 14, 3:02PM CDT

SAN DIEGO , May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical...

INBX : 91.96 (+4.06%)
Will INBX Continue Burning Cash While Markets Price In Miracles That Haven't Arrived? Barchart - Tue May 12, 4:06PM CDT

Barchart Research What to Expect from INBX Earnings INBX Generated May 12, 2026 Current Price $108.65 EPS Estimate $$-2.37 Consensus Rating Moderate Buy Average Move 4.55% Will INBX Continue Burning Cash...

INBX : 91.96 (+4.06%)
MarketBeat.com
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study MarketBeat - Mon May 11, 11:08AM CDT

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with...

INBX : 91.96 (+4.06%)
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy PR Newswire - Mon May 11, 7:00AM CDT

SAN DIEGO , May 11, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 91.96 (+4.06%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC PR Newswire - Fri May 8, 3:00PM CDT

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –

INBX : 91.96 (+4.06%)
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire - Tue Apr 21, 3:05PM CDT

SAN DIEGO , April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 91.96 (+4.06%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire - Mon Apr 20, 4:03PM CDT

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT –

INBX : 91.96 (+4.06%)

Barchart Exclusives

Mark Cuban Says 61% of Americans Are ‘Part Of The Healthcare Problem’ — If You Own Stocks in Insurance Companies You’re Putting Profit Over People Barchart - 7 minutes ago
Mark Cuban says 61% of Americans may be contributing to high healthcare costs through investments in insurance companies—and urges investors to demand change. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.